For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These groundbreaking therapies protect the transthyretin protein, slowing its destructive build-up and reducing the impact of the condition . People are now re